BACKGROUND: Glucagon-like peptide-1 (GLP-1) is a powerful insulin secretagogue that is secreted in response to meal ingestion. The ability to quantify the effect of GLP-1 on insulin secretion could provide insights into the pathogenesis and treatment of diabetes. We used a modification of a model of GLP-1 action on insulin secretion using data from a hyperglycemic clamp with concomitant GLP-1 infusion. We tested this model using data from a mixed meal test (MMT), thereby measuring GLP-1-induced potentiation of insulin secretion in response to a meal. MATERIALS AND METHODS: The GLP-1 model is based on the oral C-peptide minimal model and assumes that over-basal insulin secretion depends linearly on GLP-1 concentration through the parameter Π, representing the β-cell sensitivity to GLP-1. The model was tested on 62 subjects across the spectrum of glucose tolerance (age, 53 ± 1 years; body mass index, 29.7 ± 0.6 kg/m(2)) studied with an MMT and provided a precise estimate of both β-cell responsivity and Π indices. By combining Π with a measure of L-cell responsivity to glucose, one obtains a potentiation index (PI) (i.e., a measure of the L-cell's function in relation to prevailing β-cell sensitivity to GLP-1). RESULTS: Model-based measurement of GLP-1-induced insulin secretion demonstrates that the PI is significantly reduced in people with impaired glucose tolerance, compared with those with normal glucose tolerance. CONCLUSIONS: We describe a model that can quantitate the GLP-1-based contribution to insulin secretion in response to meal ingestion. This methodology will allow a better understanding of β-cell function at various stages of glucose tolerance.
BACKGROUND:Glucagon-like peptide-1 (GLP-1) is a powerful insulin secretagogue that is secreted in response to meal ingestion. The ability to quantify the effect of GLP-1 on insulin secretion could provide insights into the pathogenesis and treatment of diabetes. We used a modification of a model of GLP-1 action on insulin secretion using data from a hyperglycemic clamp with concomitant GLP-1 infusion. We tested this model using data from a mixed meal test (MMT), thereby measuring GLP-1-induced potentiation of insulin secretion in response to a meal. MATERIALS AND METHODS: The GLP-1 model is based on the oral C-peptide minimal model and assumes that over-basal insulin secretion depends linearly on GLP-1 concentration through the parameter Π, representing the β-cell sensitivity to GLP-1. The model was tested on 62 subjects across the spectrum of glucose tolerance (age, 53 ± 1 years; body mass index, 29.7 ± 0.6 kg/m(2)) studied with an MMT and provided a precise estimate of both β-cell responsivity and Π indices. By combining Π with a measure of L-cell responsivity to glucose, one obtains a potentiation index (PI) (i.e., a measure of the L-cell's function in relation to prevailing β-cell sensitivity to GLP-1). RESULTS: Model-based measurement of GLP-1-induced insulin secretion demonstrates that the PI is significantly reduced in people with impaired glucose tolerance, compared with those with normal glucose tolerance. CONCLUSIONS: We describe a model that can quantitate the GLP-1-based contribution to insulin secretion in response to meal ingestion. This methodology will allow a better understanding of β-cell function at various stages of glucose tolerance.
Authors: Marco Campioni; Gianna Toffolo; Lynne T Shuster; F John Service; Robert A Rizza; Claudio Cobelli Journal: Am J Physiol Endocrinol Metab Date: 2006-07-25 Impact factor: 4.310
Authors: Claudio Cobelli; Gianna Maria Toffolo; Chiara Dalla Man; Marco Campioni; Paolo Denti; Andrea Caumo; Peter Butler; Robert Rizza Journal: Am J Physiol Endocrinol Metab Date: 2007-03-06 Impact factor: 4.310
Authors: Gerlies Bock; Chiara Dalla Man; Francesco Micheletto; Rita Basu; Paula D Giesler; Jeanette Laugen; Carolyn F Deacon; Jens J Holst; Gianna Toffolo; Claudio Cobelli; Robert A Rizza; Adrian Vella Journal: Clin Endocrinol (Oxf) Date: 2009-12-18 Impact factor: 3.478
Authors: Chiara Dalla Man; Gerlies Bock; Paula D Giesler; Denise B Serra; Monica Ligueros Saylan; James E Foley; Michael Camilleri; Gianna Toffolo; Claudio Cobelli; Robert A Rizza; Adrian Vella Journal: Diabetes Care Date: 2008-10-17 Impact factor: 17.152
Authors: Meera Shah; Marcello C Laurenti; Chiara Dalla Man; Jing Ma; Claudio Cobelli; Robert A Rizza; Adrian Vella Journal: Metabolism Date: 2018-12-23 Impact factor: 8.694
Authors: Tamara S Hannon; Steven E Kahn; Kristina M Utzschneider; Thomas A Buchanan; Kristen J Nadeau; Philip S Zeitler; David A Ehrmann; Silva A Arslanian; Sonia Caprio; Sharon L Edelstein; Peter J Savage; Kieren J Mather Journal: Diabetes Obes Metab Date: 2017-06-22 Impact factor: 6.577
Authors: Alexandra G Yunker; Shan Luo; Sabrina Jones; Hilary M Dorton; Jasmin M Alves; Brendan Angelo; Alexis DeFendis; Trevor A Pickering; John R Monterosso; Kathleen A Page Journal: J Clin Endocrinol Metab Date: 2021-03-08 Impact factor: 5.958